Presentation is loading. Please wait.

Presentation is loading. Please wait.

Combined proteasome and histone deacetylase inhibition attenuates epithelial– mesenchymal transition through E-cadherin in esophageal cancer cells  Matthew.

Published byLouise Lewis Modified over 6 years ago

Similar presentations

Presentation on theme: "Combined proteasome and histone deacetylase inhibition attenuates epithelial– mesenchymal transition through E-cadherin in esophageal cancer cells  Matthew."— Presentation transcript:

1 Combined proteasome and histone deacetylase inhibition attenuates epithelial– mesenchymal transition through E-cadherin in esophageal cancer cells  Matthew D. Taylor, MD, Yuan Liu, MD, PhD, Alykhan S. Nagji, MD, Nicholas Theodosakis, BS, David R. Jones, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 139, Issue 5, Pages e1 (May 2010) DOI: /j.jtcvs Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

2 Figure 1 Two-dimensional esophageal cancer invasion decreased with vorinostat and bortezomib (Bortez) treatment after induction of epithelial–mesenchymal transition. A, Treatment with vorinostat and bortezomib in esophageal squamous carcinoma (TE2) resulted in significantly decreased cell invasion. B, Treatment with vorinostat and bortezomib in esophageal adenocarcinoma (SKGT4) resulted in significantly decreased cell invasion. Crosshatch denotes P < .05 for control versus for tumor necrosis factor (TNF) and transforming growth factor (TGF). Asterisk denotes P < .01 for treatment group versus tumor necrosis factor and transforming growth factor. Plus sign denotes P < .05 for bortezomib treatment group versus combined vorinostat and bortezomib treatment group. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

3 Figure 2 Combined vorinostat and bortezomib (Bortez) treatment induced modest esophageal cancer cell death in both squamous carcinoma (TE2) and adenocarcinoma (SKGT4) histologic subtypes after 24 hours of treatment. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

4 Figure 3 Metastasis suppressor gene transcription (CDH1, gene for E-cadherin; BRMS1, breast cancer metastasis suppressor 1 gene; NME1, gene for NM23A; ARHGDIB, gene for Rho guanosine diphosphate dissociation inhibitor [RhoGDI2], CD44; KISS1, gene for KiSS-1) after induction of epithelial-mesenchymal transition and with treatment with vorinostat, bortezomib (Bortez), or both. E-cadherin transcription was significantly upregulated in both esophageal squamous (TE2) and adenocarcinoma cell lines (SKGT4) after combined treatment of vorinostat and bortezomib. In squamous esophageal cancer, combined vorinostat and bortezomib resulted in increased nm23 and RhoGDI2 transcription. Asterisk denotes P < .01 for treatment group versus tumor necrosis factor and transforming growth factor. Plus sign denotes P < .05 for bortezomib treatment versus combined vorinostat and bortezomib treatment. Crosshatch denotes P < .05 for vorinostat treatment versus combined vorinostat and bortezomib treatment. Caret denotes P < .05 for control versus tumor necrosis factor (TNF) and transforming growth factor (TGF). mRNA- Messenger RNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

5 Figure 4 E-cadherin gene promoter activity was increased with combined treatment with vorinostat and bortezomib in both esophageal squamous carcinoma (TE2) and adenocarcinoma (SKGT4). Plus sign denotes P < .05 for vorinostat treatment versus bortezomib (Bort) treatment. Crosshatch denotes P < .05 for bortezomib treatment versus combined vorinostat and bortezomib treatment. Asterisk denotes P < .02 for given treatment group versus tumor necrosis factor and transforming growth factor. Caret denotes P < .05 for control versus tumor necrosis factor (TNF) and transforming growth factor (TGF). RLU, Relative luminescence units; Bgal, β-galactosidase. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

6 Figure 5 Combined treatment with vorinostat (Vorino) and bortezomib (Bort) induces protein expression of E-cadherin in esophageal cancer (TE2) cells. TNF, Tumor necrosis factor; TGF, transforming growth factor. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

7 Figure 6 Three-dimensional esophageal cancer metastasis decreased with combined vorinostat (V) and bortezomib (B) treatment. Addition of E-cadherin–blocking antibody (E-cad anti) to tumor cells treated with vorinostat and bortezomib induced increased metastasis in both squamous carcinoma (TE2, A) and adenocarcinoma (SKGT4, B) cell lines. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

8 A, Morphologic analysis of SKGT4 cell line associated with treatment groups. Tumor necrosis factor α (TNF) and transforming growth factor β (TGFβ) treatment demonstrated increased mesenchymal cell morphology associated with induction of epithelial–mesenchymal transition. Treatment with vorinostat, bortezomib (Bortez), or both (V+B) restored epithelial phenotype from mesenchymal phenotype. B, Real-time polymerase chain reaction demonstrated significant upregulation of vimentin and N-cadherin after treatment with tumor necrosis factor α and transforming growth factor β. Asterisk denotes P < .05 for control versus tumor necrosis factor α and transforming growth factor β. Crosshatch denotes P < .03 for control versus tumor necrosis factor α and transforming growth factor β. mRNA, Messenger RNA; GAPDH, gene for glyceraldehyde-3-phosphate dehydrogenase. The Journal of Thoracic and Cardiovascular Surgery  , e1DOI: ( /j.jtcvs ) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

Download ppt "Combined proteasome and histone deacetylase inhibition attenuates epithelial– mesenchymal transition through E-cadherin in esophageal cancer cells  Matthew."

Similar presentations

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
From: Glucose Infusion Suppresses Surgery-induced Muscle Protein Breakdown by Inhibiting Ubiquitin-proteasome Pathway in Rats Anesthes. 2009;110(1):81-88.

From: Glucose Infusion Suppresses Surgery-induced Muscle Protein Breakdown by Inhibiting Ubiquitin-proteasome Pathway in Rats Anesthes. 2009;110(1):81-88.
INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma  Christopher W. Seder, MD, Wibisono.

INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma  Christopher W. Seder, MD, Wibisono.
Stephen R. Broderick, MD, MPHS 

Stephen R. Broderick, MD, MPHS 
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A2  David Mauchley, MD, Xianzhong Meng, MD, PhD, Thomas.

Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A2  David Mauchley, MD, Xianzhong Meng, MD, PhD, Thomas.
Heat shock protein 27: Induction by gastroduodenal reflux in vivo and augmentation of human esophageal mucosal cell growth in vitro  David Mauchley, MD,

Heat shock protein 27: Induction by gastroduodenal reflux in vivo and augmentation of human esophageal mucosal cell growth in vitro  David Mauchley, MD,
Induction by left ventricular overload and left ventricular failure of the human Jumonji gene (JARID2) encoding a protein that regulates transcription.

Induction by left ventricular overload and left ventricular failure of the human Jumonji gene (JARID2) encoding a protein that regulates transcription.
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.
MicroRNA-30b is a multifunctional regulator of aortic valve interstitial cells  Mi Zhang, MD, Xiaohong Liu, MD, Xiwu Zhang, MD, Zhigang Song, MD, Lin Han,

MicroRNA-30b is a multifunctional regulator of aortic valve interstitial cells  Mi Zhang, MD, Xiaohong Liu, MD, Xiwu Zhang, MD, Zhigang Song, MD, Lin Han,
High-mobility group box-1 protein induces osteogenic phenotype changes in aortic valve interstitial cells  Bo Wang, PhD, Fei Li, MD, Chao Zhang, PhD,

High-mobility group box-1 protein induces osteogenic phenotype changes in aortic valve interstitial cells  Bo Wang, PhD, Fei Li, MD, Chao Zhang, PhD,
WT1 Promotes Invasion of NSCLC via Suppression of CDH1

WT1 Promotes Invasion of NSCLC via Suppression of CDH1
Zhao Jing, M. D. , Zhang Qiong, M. D. , Wang Yonggang, M. D

Zhao Jing, M. D. , Zhang Qiong, M. D. , Wang Yonggang, M. D
Twist-related protein 1 negatively regulated osteoblastic transdifferentiation of human aortic valve interstitial cells by directly inhibiting runt-related.

Twist-related protein 1 negatively regulated osteoblastic transdifferentiation of human aortic valve interstitial cells by directly inhibiting runt-related.
An unusual presentation of esophageal metastasis from breast cancer

An unusual presentation of esophageal metastasis from breast cancer
Differential expression of Hedgehog/Notch and transforming growth factor-β in human abdominal aortic aneurysms  Adam J. Doyle, MD, Eileen M. Redmond,

Differential expression of Hedgehog/Notch and transforming growth factor-β in human abdominal aortic aneurysms  Adam J. Doyle, MD, Eileen M. Redmond,
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo  Jessica A. Yu, MD, David Mauchley, MD, Howard Li, MD, Xianzhong.

Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo  Jessica A. Yu, MD, David Mauchley, MD, Howard Li, MD, Xianzhong.
INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma  Christopher W. Seder, MD, Wibisono.

INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma  Christopher W. Seder, MD, Wibisono.
Differential responses of the right ventricle to abnormal loading conditions in vivo: Possible pathophysiologic mechanisms  Anthony Azakie, MD, Jeffrey.

Differential responses of the right ventricle to abnormal loading conditions in vivo: Possible pathophysiologic mechanisms  Anthony Azakie, MD, Jeffrey.
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma  Mor-Li Hartman, PhD, John Matthew Esposito, BA, Beow Yong.

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma  Mor-Li Hartman, PhD, John Matthew Esposito, BA, Beow Yong.
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

Similar presentations

Ads by Google